<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30259975</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>27</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1097-0215</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>27</Day>                    </PubDate>                </JournalIssue>                <Title>International journal of cancer</Title>                <ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.31898</ELocationID>            <Abstract>                <AbstractText>Bromodomain and Extra-Terminal (BET) proteins are historically involved in regulating gene expression and BRD4 was recently found to be involved in DNA damage regulation. Aims of this study were to assess BRD4 regulation in homologous recombination-mediated DNA repair and to explore novel clinical strategies through the combinations of the pharmacological induction of epigenetic BRCAness in BRCA1 wild-type triple negative breast cancer (TNBC) cells by means of BET inhibitors and compounds already available in clinic. Performing a dual approach (chromatin immunoprecipitation and RNA interference), the direct relationship between BRD4 and BRCA1/RAD51 expression was confirmed in TNBC cells. Moreover, BRD4 pharmacological inhibition using two BET inhibitors (JQ1 and GSK525762A) induced a dose-dependent reduction in BRCA1 and RAD51 levels and is able to hinder homologous recombination-mediated DNA damage repair, generating a BRCAness phenotype in TNBC cells. Furthermore, BET inhibition impaired the ability of TNBC cells to overcome the increase in DNA damage following platinum salts (i.e. CDDP) exposure, leading to massive cell death, and triggered synthetic lethality when combined with PARP inhibitors (i.e. AZD2281). Altogether, the present study confirms that BET proteins directly regulate the homologous recombination pathway and their inhibition induced a BRCAness phenotype in BRCA1 wild-type TNBC cells. Noteworthy, being this strategy based on drugs already available for human use, it is rapidly transferable and could potentially enable clinicians to exploit platinum salts and PARP inhibitors-based treatments in a wider population of TNBC patients and not just in a specific subgroup, after validating clinical trials. This article is protected by copyright. All rights reserved.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Mio</LastName>                    <ForeName>C</ForeName>                    <Initials>C</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-6245-8266</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gerratana</LastName>                    <ForeName>L</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bolis</LastName>                    <ForeName>M</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Biology, Mario Negri Institute for Pharmacological Research, 20156, Milano, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Caponnetto</LastName>                    <ForeName>F</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zanello</LastName>                    <ForeName>A</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Barbina</LastName>                    <ForeName>M</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Life Sciences, University of Trieste, 34127, Trieste, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Di Loreto</LastName>                    <ForeName>C</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Pathology, ASUIUD University Hospital of Udine, 33100, Udine, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Garattini</LastName>                    <ForeName>E</ForeName>                    <Initials>E</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8983-886X</Identifier>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Biology, Mario Negri Institute for Pharmacological Research, 20156, Milano, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Damante</LastName>                    <ForeName>G</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Medical Genetics, ASUIUD University Hospital of Udine, 33100, Udine, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Puglisi</LastName>                    <ForeName>F</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Oncology, IRCCS CRO Aviano National Cancer Institute, 33081, Aviano, Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Int J Cancer</MedlineTA>            <NlmUniqueID>0042124</NlmUniqueID>            <ISSNLinking>0020-7136</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">BET inhibitors</Keyword>            <Keyword MajorTopicYN="N">BRCAness</Keyword>            <Keyword MajorTopicYN="N">Triple Negative Breast Neoplasms</Keyword>            <Keyword MajorTopicYN="N">homologous recombination</Keyword>            <Keyword MajorTopicYN="N">synthetic lethality</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30259975</ArticleId>            <ArticleId IdType="doi">10.1002/ijc.31898</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>